Grants
Most founders should not build their funding strategy around grants.
execom helps founders separate useful non-dilutive funding from slow, distracting grant-chasing.
Grants can be valuable. They can also consume time, add compliance drag, and create false hope. In most cases, founders should focus first on SR&ED and other lower-friction capital that supports work they already need to do.
Overview
Grants are a tool, not a strategy. They are one component of a non-dilutive capital stack — and for most founders, they are not the component that should come first.
Founders often chase grants for emotional reasons: validation, runway anxiety, the appeal of money that feels free. But non-dilutive capital should be evaluated like any other resource — by friction, odds, timing, and strategic alignment with work the company already needs to do.
For Canadian founders in particular, SR&ED is often the highest-priority non-dilutive mechanism. It rewards work already underway, aligns with the company's actual technical roadmap, and does not require winning a competition.
Odds
Most competitive grant programs have low success rates. Founders routinely overestimate their chances and underestimate the pool of applicants.
Delay
From application to decision to disbursement, grant timelines are almost always longer than founders expect. Months of work can yield nothing.
Compliance
Winning a grant is not the end. Reporting, documentation, audits, and milestone tracking create ongoing administrative drag that persists long after the award.
Focus
Every hour spent on a grant application is an hour not spent on product, customers, or revenue. The opportunity cost is real and usually underpriced.
What Actually Matters
Not all non-dilutive funding is created equal.
Founders should prioritize capital sources by reliability, speed, alignment with actual roadmap, administrative burden, and probability-adjusted value. When you apply those filters honestly, the hierarchy becomes clear.
| SR&ED | IRAP / R&D Support | Traditional Grants | |
|---|---|---|---|
| Speed | Filed with tax return; refunds within weeks to months | Application-based; moderate review cycles | Slow — months from application to decision, often longer to disbursement |
| Certainty | High — based on qualifying work already done | Moderate — competitive but with clearer criteria | Low — competitive, subjective, and often unpredictable |
| Admin Burden | Documentation of technical work; manageable with proper systems | Milestone reporting and financial tracking | Heavy — proposals, budgets, reports, audits, compliance reviews |
| Dependence Risk | Low — rewards past work, not future promises | Low to moderate — tied to specific projects | High — builds expectation of continued grant reliance |
| Founder Distraction | Minimal if properly structured | Moderate — application and reporting overhead | Significant — can consume weeks of founder time per application |
| Strategic Fit | Directly aligned with R&D the company is already doing | Usually aligned with technical roadmap | Often requires contorting roadmap to match grant criteria |
SR&ED and pragmatic low-friction programs come first. Traditional grants are conditional and secondary.
Know which non-dilutive capital actually deserves your attention.
execom helps founders prioritize the funding mechanisms that fit — and stop wasting time on the ones that do not.
Signature Section
The Canada Factor
Why Canadian founders get pushed toward grants — and why that often becomes a trap.
Canada's capital environment pushes founders toward non-dilutive funding earlier than in the United States. That part is rational. The problem is that many founders then over-rotate into slow, competitive grant programs instead of focusing on the highest-leverage options first. In Canada, the right answer is often not “more grants.” It is sharper prioritization: SR&ED first, practical support second, grant-chasing only when tightly justified.
Canada has smaller capital pools, slower fundraising cycles, smaller check sizes, and fewer acquirers. This makes founders understandably hungry for non-dilutive money. The instinct is correct — reducing dilution is smart. The mistake is letting that hunger drive founders toward whichever programs appear most available rather than which ones are actually highest-leverage.
When capital is scarce, founders start seeing grants as salvation. Applications feel productive — they involve strategy, writing, financial modeling, timelines. But activity is not progress. A grant application that takes three weeks and has a low acceptance rate is not a capital strategy. It is busywork with a lottery ticket attached. Founders who replace traction-building with grant-chasing rarely come out ahead.
Canadian enterprise adoption is slower and the domestic market is smaller. This means founders already face longer timelines to prove traction and generate revenue. A grant process — with its own months-long cycle — layered on top of an already slow market creates compounding delay. Time spent waiting on grant decisions is time not spent converting customers or demonstrating the growth that investors and partners actually care about.
For many Canadian innovation companies, SR&ED is the real workhorse of non-dilutive capital. It aligns with actual R&D spend, rewards work already being done, and operates on a fundamentally different model than competitive grants. SR&ED does not require winning a pitch competition or aligning your roadmap with someone else's priorities. It is usually more strategically important — and more financially significant — than spending months chasing uncertain grants. Most founders underuse it.
execom exists to help founders prioritize the right non-dilutive capital, structure SR&ED claims properly, avoid grant-chasing as a substitute for strategy, and use funding as leverage rather than as a crutch. The Canadian ecosystem does not need more grant directories. It needs better judgment about what is actually worth pursuing.
Canadian founders do not need more funding folklore. They need a hierarchy of what is actually worth pursuing.
Grant Reality
The honest version of how grant programs work for most founders.
Every grant has a cost: the time to apply, the constraints on how funds are used, the compliance obligations that follow, and the opportunity cost of what the founder could have been doing instead. The nominal dollar amount is almost never the real value once friction is accounted for. Founders who think of grants as free money are miscalculating the cost of their own time.
Most competitive grant programs have acceptance rates that would discourage founders if they saw the numbers clearly. Rejection is normal, not exceptional. Founders routinely overestimate their chances because the application process feels serious and professional — but feeling competitive and being competitive are different things. Expecting to win a grant is not a capital strategy.
From application to decision, weeks become months. From decision to disbursement, more months pass. Many grant programs operate on reimbursement models, meaning the company must spend the money first and recover it later — sometimes much later. Founders who factor grant funds into near-term cash flow projections are building on assumptions that frequently collapse.
Winning a grant starts a reporting relationship. Milestone tracking, financial documentation, progress reports, and potential audits create an administrative tail that extends well beyond the initial award. This overhead is real, ongoing, and almost always underestimated at application time.
A business model that depends on grant funding to stay viable is not a business model. Grants should supplement a company that is already functional without them. If removing the grant from the financial model causes the company to fail, the problem is not the grant — it is the business.
SR&ED First
Start with SR&ED.
For many Canadian founders, this is the non-dilutive priority that matters most.
SR&ED is not speculative. It is based on qualifying technical work your company has already done. It does not require a pitch, a competition, or contorting your roadmap. It aligns with actual R&D spend and rewards genuine innovation work. For many Canadian innovation companies, SR&ED represents the largest single source of non-dilutive capital available — and it is routinely underleveraged.
The fundamental difference between SR&ED and traditional grants is the direction of the bet. SR&ED recovers money on work already performed. Grants ask you to predict and promise work that may or may not unfold as proposed. One is grounded. The other is speculative. Founders should exhaust the grounded option before investing heavily in the speculative one.
Many founders think SR&ED is only for large companies, requires complex filings they cannot handle, or produces insignificant returns. None of this is accurate. Early-stage companies with genuine technical work often qualify for meaningful claims. The problem is usually not eligibility — it is awareness, documentation habits, and the quality of advisory support.
SR&ED should be the foundation layer of a non-dilutive capital strategy. It provides a reliable, recurring source of capital that strengthens the company's position before layering on other instruments — whether that is IRAP, selective grants, revenue-based financing, or equity. Every other non-dilutive decision should be made after SR&ED is properly structured.
If your company is doing qualifying technical work in Canada, ignoring SR&ED while chasing grants is usually backwards.
Is your SR&ED structured correctly?
Most founders leave money on the table. execom helps structure SR&ED claims before layering on other non-dilutive capital.
IRAP & Practical Programs
Practical programs worth evaluating.
This is not a directory. It is a short list of program categories that — under the right conditions — can be worth the founder's time. The filter is simple: does it fund work you were already doing, at an acceptable administrative cost, without pulling the company off course?
The National Research Council's Industrial Research Assistance Program provides advisory services and funding for R&D projects. For early-stage companies, IRAP can be a meaningful complement to SR&ED — covering project-specific costs with a relatively clear application process and assigned advisors. It works best when the project scope is well-defined and the company already has technical capacity to execute.
Several provinces offer innovation support that, for the right company, can be worth pursuing. Alberta Innovates, Ontario's programs, and similar provincial instruments have varying relevance depending on geography, sector, and stage. The key is selectivity — not applying to everything available, but targeting the programs that genuinely fit.
For companies already planning cross-border or international go-to-market, certain trade and export support programs can reduce the cost of market entry. These make sense when the company is already committed to the expansion — not when the grant is the reason for expanding.
Programs that fund specific technical development — not general operations — can be useful when the project already exists on the roadmap. The test is simple: would you do this work without the funding? If yes, the program is an accelerant. If no, the program is pulling you off course.
Some non-dilutive programs can be combined with SR&ED claims, effectively increasing the total recovery on qualifying work. Understanding how instruments interact — what stacks, what offsets, and what creates audit complexity — is part of structuring a non-dilutive capital strategy properly rather than treating each program in isolation.
When Grants Make Sense
Grants are not always wrong. There are specific conditions under which they are worth pursuing. The page would be dishonest if it said otherwise.
Companies with genuinely long development timelines — biotech, advanced materials, hardware with multi-year R&D cycles — often have a stronger case for grant funding. The timeline mismatch between venture capital expectations and deep-tech reality means non-dilutive capital can be structurally important, not just convenient.
When the grant-giving body is also a potential customer or procurement partner, the relationship has value beyond the dollars. Defence, health, infrastructure, and public safety verticals sometimes offer grants that double as market validation and customer development.
If the company was going to do the work anyway, and the grant criteria happen to match, the marginal cost of applying is lower and the strategic distortion is minimal. This is the cleanest use case — the grant accelerates existing motion rather than creating new motion for its own sake.
A two-person team burning through its last six months of runway should not be writing grant applications. A team with 18 months of runway, a dedicated operations person, and a clear project scope is in a different position. Grants require organizational capacity that early-stage founders rarely have.
The clearest signal that a grant is worth pursuing: removing it from the plan would not change the company's direction. It would only change the speed. If the grant is the reason the project exists, that is a dependency. If the grant makes an existing project faster, that is leverage.
Grants are best used as accelerants for motion that already exists, not as substitutes for motion.
Stop chasing. Start prioritizing.
execom helps founders build a non-dilutive capital strategy that starts with what works and treats grants as conditional.
Founder Mistakes
The patterns that cost founders the most when it comes to non-dilutive capital.
01
Treating grants as strategy
Grants are a tool. When they become the plan, the company is building on someone else's timeline, criteria, and approval process.
02
Ignoring SR&ED
The highest-leverage non-dilutive capital for most Canadian innovation companies. Underusing it while chasing grants is usually backwards.
03
Applying before checking fit
Submitting applications to programs that do not match the company's stage, sector, or activities wastes time and builds false hope.
04
Designing roadmap around the grant
When the grant criteria start shaping what the company builds, the company has lost strategic autonomy for conditional money.
05
Underestimating founder time cost
Multiple grant applications per year can consume a meaningful share of the founder's productive capacity. That time had a value.
06
Assuming reimbursement timing
Building cash flow projections around expected grant disbursements is a structural risk. Delays are normal, not exceptional.
07
Failing to build documentation early
Poor records at the time of spending create compliance problems months or years later — for both grants and SR&ED.
08
Depending on grants to validate
Winning a grant is not market validation. Customers paying for your product is validation. Do not confuse the two.
FAQ
Sometimes — but far less often than founders assume. Grants are worth it when the project already fits, the company can absorb the timeline and compliance burden, and the grant supplements work that would happen anyway. For most early-stage startups, other non-dilutive instruments should come first.
SR&ED. For companies doing qualifying technical work, it is usually the highest-leverage, most reliable, and least distracting source of non-dilutive capital. After SR&ED is properly structured, evaluate IRAP and selective practical programs. Competitive grants come last — and only when tightly aligned.
For most qualifying Canadian companies, yes. SR&ED rewards work already done, operates on a more predictable timeline, and does not require winning a competition. It should typically be optimized before serious grant-chasing begins.
SR&ED is a federal tax incentive that provides refundable credits for qualifying R&D expenditures — it is retroactive and based on work already performed. IRAP is a project-based funding program through the National Research Council that provides advisory and financial support for specific R&D projects — it is prospective and requires an application. They can complement each other but operate on different models.
Deep tech with long development cycles, government-as-customer situations, projects already aligned with grant criteria, and teams with enough runway and administrative capacity to absorb the process. The test: would you do this work without the grant? If yes, apply. If no, reconsider.
Yes. When grants consume disproportionate founder time, distort the roadmap, create dependency, or delay traction-building activities, the net effect is negative. The dollar amount of the grant can be smaller than the opportunity cost of pursuing it.
Ensure SR&ED is structured. Confirm the grant criteria genuinely match your current work. Estimate the realistic time cost of the application. Check whether the program operates on reimbursement and model the cash flow impact. Ask honestly: is this the best use of the next three weeks of my time?
No. A business that depends on winning grants to stay viable is not a business — it is a grant-dependent organization. Grants should supplement a company that is already functional without them. If the grant disappears and the company fails, the problem was never the grant.
Do not confuse non-dilutive funding with easy money.
The right funding can extend runway and strengthen your position. The wrong pursuit can drain attention, delay traction, and create false confidence. execom helps founders focus on the non-dilutive capital that actually matters.